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Abstract
Background: Impaired myocardial perfusion reserve (MPR) is prevalent in obesity and diabetes, even in the
absence of obstructive coronary artery disease (CAD), and is prognostic of adverse events. We sought to establish
the time course of reduced MPR and to investigate associated vascular and tissue properties in mice fed a high-fat
diet (HFD), as they are an emerging model of human obesity, diabetes, and reduced MPR without obstructive CAD.
Methods: C57Bl/6 mice fed a HFD or a low-fat diet (control) were imaged at 6, 12, 18 and 24 weeks post-diet. The
cardiovascular magnetic resonance (CMR) protocol included multi-slice cine imaging to assess ejection fraction (EF),
left-ventricular (LV) mass, LV wall thickness (LVWT), and LV volumes, and first-pass perfusion CMR to quantify MPR.
Coronary vascular reactivity, aortic atherosclerosis, myocardial capillary density and tissue fibrosis were also assessed.
Results: Body weight was increased in HFD mice at 6–24 weeks post-diet (p < 0.05 vs. control). MPR in HFD mice
was reduced and LV mass and LVWT were increased in HFD mice at 18 and 24 weeks post-diet (p < 0.05 vs.
control). Coronary arteriolar vascular reactivity to adenosine and acetylcholine were reduced in HFD mice (p < 0.05
vs. control). There were no significant differences in cardiac volumes, EF, or capillary density measurements
between the two groups. Histology showed interstitial fibrosis in HFD and no aortic atherosclerosis in either group.
Conclusions: C57Bl/6 mice fed a HFD for 18–24 weeks have progressively increased LV mass and impaired MPR
with fibrosis, normal capillary density and no aortic plaque. These results establish C57Bl/6 mice fed a HFD for
18–24 weeks as a model of impaired MPR without obstructive CAD due to obesity and diabetes.
Keywords: Myocardial perfusion reserve, Mouse, Cardiovascular magnetic resonance, Obesity, Type 2 diabetes mellitus
Abbreviations: AIF, Arterial input function; ANOVA, Analysis of variance; AUC, Area under the curve; BLOSM, Block
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Background
For several decades the prevailing practice in the treat-
ment of ischemic heart disease has equated myocardial
ischemia with obstructive coronary artery disease (CAD)
[1]. Accordingly, most therapies for myocardial ischemia
aim to remove coronary stenoses. However, there is
mounting evidence that not all patients with ischemia
have obstructive CAD, and a paradigm shift has been
proposed [1]. The emerging concept is that multiple fac-
tors including microvascular disease, coronary vaso-
spasm, and others may be significant contributors to
myocardial ischemia, and that obstructive CAD is
one of multiple potential causes [1]. Indeed, studies
have shown that myocardial ischemia in the absence
of obstructive CAD occurs with considerable preva-
lence in certain patient populations including dia-
betics [2], obesity [3], the metabolic syndrome [4]
and women [5].
The presence and severity of myocardial ischemia can
be assessed quantitatively by imaging myocardial perfu-
sion reserve (MPR) using PET or cardiovascular mag-
netic resonance (CMR). Reduced MPR has been shown
to be prognostic of adverse cardiovascular events and an
independent predictor of cardiac mortality in patients
with and without obstructive CAD [6]. One recent study
with more than 1000 diabetic and 1600 non-diabetic
subjects showed that diabetic patients without obstruct-
ive CAD but with impaired MPR have the same event
rate as non-diabetic patients with prior CAD [2]. In the
absence of obstructive CAD, impaired MPR largely
reflects dysfunction of the resistance vessels of the mi-
crovasculature. While microvascular dysfunction leads
to reduced MPR and increased cardiovascular risk, the
mechanisms underlying microvascular dysfunction are
not completely understood, and corresponding treat-
ment strategies are not established.
Mouse models are widely utilized in cardiovascular
research to study underlying molecular mechanisms,
and mice fed a high-fat diet (HFD) are emerging as a
common model of human obesity and diabetes. A recent
study characterized the long term effects of a HFD on
the cardiovascular system in mice and found that mice
fed a HFD for 8–16 months develop obesity, hypergly-
cemia, hyperinsulinemia, insulin resistance, cardiomyo-
cyte hypertrophy and cardiac metabolic maladaptations
[7]. Another recent study used CMR to show that HFD
mice develop diastolic dysfunction after 20 weeks of diet
[8]. In addition, we recently used first-pass contrast-
enhanced perfusion CMR to demonstrate that HFD mice
have impaired MPR at 24 weeks after initiating the diet
[9]. In the present study we sought to establish the time
course and investigate vascular and tissue properties
underlying the progression of increased LV mass and
reduced MPR in HFD mice.
Methods
Experimental design
Two groups of mice were studied: C57Bl/6 mice fed a
HFD (n = 11) (60 % calories from fat, Diet 12492, Research
Diets Inc., New Brunswick, NJ) and age-matched C57Bl/6
control mice fed a low-fat diet (n = 9) (10 % calories from
fat, Diet D12450J, Research Diets Inc.). Male mice were
selected for this study as prior studies have shown that fe-
male C57Bl/6 mice are protected against HFD-induced
glucose intolerance [10] and the development of obesity-
related cardiac dysfunction [11]. Over the course of this
study, three HFD mice and one control mouse died, bring-
ing the sample size to n = 8 in each group by the end of the
study. Mice were started on their respective diets at 6 weeks
of age, and were studied at 6, 12, 18 and 24 weeks post-
diet. The CMR protocol at all time points included (a) per-
fusion imaging at rest and with a vasodilator, (b) cine dis-
placement encoding with stimulated echoes (DENSE)
imaging to measure myocardial strain, and (c) cine CMR
to measure end-diastolic volume (EDV), end-systolic vol-
ume (ESV), ejection fraction (EF), LV mass, LV wall thick-
ness at end-diastole (LV EDWT) and LV wall thickness at
end-systole (LV ESWT). Glucose tolerance tests (GTTs)
were performed at 6, 12, 18 and 24 weeks post-diet.
Systolic blood pressure was measured in conscious mice at
25 weeks post-diet using a non-invasive tail cuff plethys-
mography system (Model BP 2000, Visitech Systems, Apex,
NC). Mice were euthanized at 26 weeks post-diet for hist-
ology and to assess coronary vascular reactivity.
Animal handling
All animal studies were performed under protocols that
comply with the Guide for the Care and Use of Laboratory
Animals (NIH publication no. 85–23, Revised 1996) and
were approved by the Animal Care and Use Committee at
our institution. An indwelling tail vein catheter was estab-
lished to deliver Gd-DTPA (Magnevist, 0.1 mM/kg body
weight) and Regadenoson (Lexiscan, Astellas Pharmis,
0.1 μg/g body weight) during CMR. Body temperature was
maintained at 36 ± 0.5 °C and anesthesia was maintained
using 1.1–1.25 % isoflurane in O2. Body weight was
recorded for all animals before starting the diets and at the
beginning of each imaging study.
Glucose tolerance tests
For GTTs [12], mice were injected intraperitoneally with
1 g/kg glucose in milli-Q water after overnight fasting
for 15–16 hours. A tail vein blood sample was taken
before injection of glucose to measure the fasting blood
glucose and at 10, 30, 60 and 90 min post-injection of
the glucose solution. The area under the curve (AUC)
was calculated to evaluate glucose tolerance using the
trapezoidal rule [7].
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CMR acquisitions
CMR was performed on a 7T Clinscan system (Bruker,
Ettlingen, Germany) using a 30–35 mm diameter bird-
cage RF coil. The bigger coil was used when necessary
to accommodate the heavier mice. Localizer imaging
was performed to select a mid-ventricular short-axis
slice. Rest perfusion was then imaged using a com-
pressed sensing (CS)-accelerated dual-contrast first-
pass sequence [9]. Using this sequence, two slices were
acquired: one to sample the arterial input function
(AIF) and the other to sample the tissue function (TF).
Imaging parameters included: echo time/repetition time
(TE/TR) = 1.2/2.1 ms, field of view (FOV) = 25.6 ×
18 mm2, matrix = 128 × 74, phase FOV = 72 %, percent
sampling = 80 %, image resolution = 200 × 250 μm2, flip
angle = 150, slice thickness = 1 mm, AIF saturation
delay = 15 ms, TF saturation delay = 57 ms, AIF acceler-
ation rate = 6, TF acceleration rate = 4, AIF acquisition
time = 25 ms/image and TF acquisition time = 36 ms/
image. Thereafter, baseline LV structure and function
were assessed using a black-blood cine CMR sequence
as described previously [13]. Six - eight short-axis slices
were acquired covering the entire LV from base to apex.
Imaging parameters included: TE/TR = 1.9/4.4 ms, tem-
poral resolution = 4.4 ms, slice thickness = 1 mm, and
image resolution = 200 μm2. Myocardial strain was then
measured in a mid-ventricular short-axis slice using the
cine-DENSE method as previously described [14, 15]. For
the cine DENSE acquisition, fat-saturation was applied
when necessary to null the signal from fat in order to im-
prove the image quality. Thereafter, Regadenoson was
injected i.v. and 10 min later first-pass CMR was repeated.
Vascular reactivity
After 26 weeks on diet, a subgroup of HFD and control
mice were euthanized and coronary arteries (n ≥ 4) from
the second arborized branches off the left coronary artery
were isolated (lumen diameter = 90.9 ± 9.5 μm). The arter-
ies were freed of the surrounding cardiac myocytes and
were placed in an arteriograph (Danish MyoTechnology,
DMT, Ann Harbor, MI), where they were cannulated at
both ends and pressurized to 40 mmHg as previously
described [16–18]. Cumulative dose-responses to adeno-
sine and acetylcholine and a step-wise pressure increase
for assessment of passive tone were measured as previ-
ously described [16–18].
Histology
Mice were euthanized for histology (n = 5, each group),
hearts were harvested and mid-ventricular short-axis
sections (3 mm thick) were fixed in 4 % paraformalde-
hyde for 4 hours and then embedded in paraffin. Sec-
tions (5 μm thick) were stained with anti-CD31 antibody
(Santa Cruz Biotechnology) to quantify capillary density,
and Masson’s Trichrome to quantify interstitial fibrosis
and perivascular fibrosis. For the assessment of systemic
atherosclerosis, ascending aortas were excised and
stained with Sudan IV.
For histology, image analysis was performed using
ImageJv1.49 g (NIH). Quantification of capillary density
was performed on 6 random fields (40x) and capillaries
and cardiomyocytes were counted using the ‘analyze par-
ticles’ function in ImageJ. Quantification of interstitial
fibrosis was performed on 15 random fields (40x)
(excluding the blood vessels) and a thresholding method
was used to quantify the area occupied by collagen as a
percentage [19]. Quantification of perivascular fibrosis
was performed on 2 arteries per mouse (40x) and the
average perivascular collagen area normalized to the ves-
sel luminal area was recorded. The aortic plaque area,
quantified using ImageJ, was expressed as a percentage
of the aortic vessel area.
Analysis of MR images
For perfusion images, image reconstruction and analysis
were performed in MATLAB (Mathworks, Natick, MA)
as previously described [9]. Undersampled first-pass per-
fusion images were reconstructed using Block LOw-rank
Sparsity with Motion-guidance (BLOSM), a motion-
compensated CS method [20]. Perfusion analysis was
based on Fermi function deconvolution [21]. Briefly,
signal intensity vs. time curves were obtained by placing
a region of interest (ROI) in the LV blood pool for the
AIF and in the myocardium for the TF. These signal
intensities were normalized by the signal intensities of
proton-density weighted images and thereafter were
converted into T1 values using the methods described
by Cernicanu and Axel [22]. The pre-contrast T1 was
fixed at 1.55 s for blood and 1.45 s for myocardium [9].
Using Fermi function deconvolution, rest and stress per-
fusion were quantified for each mouse at each time
point. MPR for each mouse at each time point was then
calculated as the ratio of stress perfusion to rest perfu-
sion. Some mice were excluded for perfusion studies due
to difficulty in repetitive placement of i.v. lines and due to
bad image quality of stress perfusion images (caused due
to motion artifacts at high heart-rates). The sample sizes
at each time point were as follows: n = 7 (HFD) and n = 6
(Control) at 6 weeks post-diet, n = 6 (HFD) and n = 6
(Control) at 12 weeks post-diet, n = 8 (HFD) and n = 9
(Control) at 18 weeks post-diet, n = 8 (HFD) and n = 7
(Control) at 24 weeks post-diet. The black-blood cine im-
ages were imported to a workstation and analyzed using
Segment software (Medviso, AB). Specifically, the end-
diastolic (ED) and end-systolic (ES) frames were identified
and thereafter the endocardial and epicardial contours
were drawn on these frames for all the slices. Using the
software, the EDV, ESV, EF, LV mass, LV EDWT and LV
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ESWT were calculated. Strain analysis of cine DENSE
images was performed using the DENSE analysis tool
[23–25], which is a semi-automatic technique imple-
mented in MATLAB. Global peak circumferential strain
(Ecc) was used as another metric of systolic function. As
done previously for HFD mice [26], subepicardial circum-
ferential strain (Ecc-subepi) and subendocardial circumfer-
ential strain (Ecc-subendo) were also assessed. Cine DENSE
strain data were also used to quantify LV synchrony
using the circumferential uniformity ratio estimate
(CURE) [27, 28].
Statistical analysis
Statistical analysis was performed using SigmaPlot (Systat
Software Inc., Point Richmond, CA). Differences in body
weight, EDV, ESV, EF, LV mass, LV EDWT, LV ESWT, rest
perfusion, stress perfusion, MPR, global Ecc, Ecc-subepi, Ecc-
subendo and CURE were analyzed using two-way repeated
measures analysis of variance (ANOVA). All values in text,
tables and graphs are presented as mean ± standard
deviation.
Results
Body mass and glucose tolerance tests
Body weight was significantly higher in the HFD mice at
6 weeks post-diet and it progressively increased with time
(Fig. 1a, p < 0.05 vs. age-matched control). The HFD mice
were hyperglycemic at 12 and 18 weeks post-diet as mea-
sured using fasting blood glucose (Fig. 1b, p < 0.05 vs. age-
matched control). The HFD mice were glucose intolerant
as compared to the control mice at 12 weeks post-diet
(Fig. 1c–d, p < 0.05 vs. age-matched control).
CMR
Perfusion
Figure 2a shows example first-pass perfusion images ob-
tained from a mouse heart. There were no differences in
the rest perfusion measurements between the two
groups of mice at any of the time points (Fig. 2b). How-
ever stress perfusion in the HFD mice was reduced as
compared to control mice at 18 and 24 weeks post-diet
(Fig. 2c, p < 0.05 vs. age-matched control). MPR was also
reduced in the HFD mice as compared to control mice
at 18 and 24 weeks post-diet (Fig. 2d, p < 0.05 vs. age-
matched control).
LV structure and function
Figure 3a shows example black-blood cine images ob-
tained from a control and a HFD mouse at ED and ES at
18 weeks post-diet. LV mass was significantly higher in
the HFD mice as compared to the control mice at 18
and 24 weeks post-diet (Fig. 3b, p < 0.05 vs. age-matched
control). LV mass progressively increased in the HFD
mice from the start of the diet to the end of the study.
We also saw a slight increase in LV mass in the control
group at 24 weeks post-diet (p < 0.05 vs. control at 6 and
12 weeks post-diet), probably due to normal growth at
their age. LV EDWT and ESWT were also significantly
Fig. 1 a Body weight measurements in mice fed high-fat diet (HFD) and low-fat diet (control) at the start of diet and 6, 12, 18 and 24 weeks post-diet
(*p < 0.05 vs. age-matched control). b Fasting blood glucose measurements in control and HFD mice at 6, 12, 18 and 24 weeks post-diet (*p < 0.05 vs.
age-matched control). c Glucose tolerance curves in the control and HFD mice at 12 weeks post-diet (*p < 0.05 vs control at the same time-point). d
The area under the curve (AUC) of the glucose tolerance test at 6, 12, 18 and 24 weeks post-diet (*p < 0.05 vs. age-matched control)
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increased in the HFD mice at 18 and 24 weeks post-diet
(Fig. 3c–d, p < 0.05 vs. age-matched control, p < 0.05 vs.
HFD at 6 and 12 weeks post-diet). There were no statis-
tically significant differences in LV EDV, LV ESV, LV EF,
LV Ecc-subendo, LV Ecc-subepi, LV global Ecc or CURE mea-
surements between the two groups of mice over the time
course (Table 1).
Blood pressure and heart rate
Systolic blood pressure at 25 weeks post-diet was found
to be 106 ± 7 mmHg in the control group and 110 ±
7 mmHg in the HFD group. Diastolic blood pressure at
25 weeks post-diet was found to be 81 ± 8 mmHg in the
control group and 80 ± 9 mmHg in the HFD group.
These differences were not statistically significant. There
were also no significant heart rate differences between
the two groups of mice for the entire time course of the
study (Table 1).
Vascular reactivity
Cumulative dose-response curves to adenosine demon-
strated a significantly decreased ability of the arterioles to
dilate in mice fed a HFD for 26 weeks (Fig. 4a, p < 0.05 vs.
control). Since loss of endothelial-dependent dilation is a
hallmark of HFD, we tested vascular reactivity to
acetylcholine, an endothelial specific dilator. Similar
to adenosine, the ability of HFD mice to dilate coron-
ary arterioles was significantly inhibited in response
to acetylcholine (Fig. 4b, p < 0.05 vs. control). Lastly,
we tested whether matrix composition may also be al-
tered in the coronary arterioles by measuring the pas-
sive tone in response to increasing pressure steps. In
the HFD mice, the passive tone was significantly
inhibited as compared to the control mice (Fig. 4c, p
< 0.05 vs. control). These results demonstrated that
the coronary arterioles in the HFD mice have a sig-
nificantly decreased capacity to dilate.
Histology
Figure 5 shows example CD31-stained images from a con-
trol (Fig. 5a) and a HFD mouse heart (Fig. 5b). There were
no significant differences in the number of capillaries per
cardiomyocyte between the two groups of mice (Fig. 5c).
Furthermore, there was no aortic atherosclerosis in either
control or HFD mice. Aortic plaque was found to be 3.7 ±
1.8 % in the control mice and 3.2 ± 1.4 % in the HFD mice.
Figure 5 shows Masson’s Trichrome stained sections of
myocardium obtained from a control mouse (Fig. 5d) and a
HFD mouse (Fig. 5e). We found increased interstitial fibro-
sis in HFD mice (Fig. 5f, p < 0.05 vs. control) at 26 weeks
post-diet. Figure 5 also shows Masson Trichrome-stained
Fig. 2 a Example first-pass perfusion images obtained from a mouse at rest. These images show the arrival of contrast agent in the right ventricle (i), left
ventricle (ii and iii) and the myocardium (iv). b Rest perfusion measurements in the control and HFD mice at 6, 12, 18 and 24 weeks post-diet. c Stress
perfusion measurements in the control and HFD mice at 6, 12, 18 and 24 weeks post-diet (*p< 0.05 vs. age-matched control). d Myocardial perfusion
reserve (MPR) measurements in the control and HFD mice (*p < 0.05 vs. age-matched control)
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coronary vessels obtained from a control mouse (Fig. 5g)
and a HFD mouse (Fig. 5h). We found a trend towards
increased perivascular fibrosis in HFD mice (Fig. 5i).
Discussion
In this study we established the time course of impaired
MPR in mice fed a HFD and related the impaired MPR
to underlying dysfunction of the coronary arterioles.
Using serial in vivo noninvasive CMR we showed pro-
gressively reduced MPR at 18 and 24 weeks of HFD in
C57Bl/6 mice without changes in capillary density and
without aortic atherosclerosis. It is established that
C57Bl/6 mice without additional genetic manipulation
do not develop obstructive atherosclerosis in the aorta
Fig. 3 a Example black-blood cine images in the control and HFD mice at end-diastole and end-systole at 18 weeks post-diet. b LV mass measurements
in the control and HFD mice at 6–24 weeks post-diet (*p< 0.05 vs. age-matched control, $p< 0.05 vs. HFD at 6 weeks, #p< 0.05 vs. HFD at 12 weeks,
&p< 0.05 vs. HFD at 18 weeks). c LV end-diastolic wall thickness (LVEDWT) measurements in the control and HFD mice at 6–24 weeks post-diet (*p< 0.05
vs. age-matched control, $p< 0.05 vs. HFD at 6 weeks, #p< 0.05 vs. HFD at 12 weeks). d LV end-systolic wall thickness (LVESWT) measurements in the
control and HFD mice at 6–24 weeks post-diet (*p < 0.05 vs. age-matched control, $p < 0.05 vs. HFD at 6 weeks, #p < 0.05 vs. HFD at 12 weeks)
Table 1 CMR parameters of cardiac function
Time (Weeks after start of diet)
6 weeks 12 weeks 18 weeks 24 weeks
Control HFD Control HFD Control HFD Control HFD
LVEDV (μL) 43 ± 7 42 ± 7 48 ± 9 47 ± 10 44 ± 7 40 ± 7 40 ± 6 43 ± 5
LVESV (μL) 17 ± 4 14 ± 4 17 ± 6 17 ± 6 16 ± 6 12 ± 5 13 ± 4 11 ± 5
LVEF (%) 61 ± 8 66 ± 8 64 ± 12 65 ± 8 64 ± 9 69 ± 12 67 ± 8 74 ± 11
Heart Rate (bpm) 530 ± 63 538 ± 88 478 ± 39 485 ± 69 450 ± 84 512 ± 62 507 ± 47 549 ± 59
Change in Heart Rate under Stress (%) 23 ± 16 28 ± 12 27 ± 5 16 ± 13 15 ± 19 21 ± 13 21 ± 28 −2 ± 15*
Ecc −0.14 ± 0.02 −0.13 ± 0.02 −0.13 ± 0.02 −0.12 ± 0.01 −0.12 ± 0.03 −0.11 ± 0.02 −0.12 ± 0.01 −0.14 ± 0.02
Ecc-subepi −0.09 ± 0.01 −0.09 ± 0.02 −0.09 ± 0.01 −0.08 ± 0.01 −0.08 ± 0.02 −0.07 ± 0.02 −0.08 ± 0.01 −0.09 ± 0.01
Ecc-subendo −0.19 ± 0.02 −0.17 ± 0.03 −0.18 ± 0.03 −0.16 ± 0.02 −0.17 ± 0.04 −0.16 ± 0.03 −0.17 ± 0.02 −0.20 ± 0.03
CURE 0.87 ± 0.06 0.85 ± 0.07 0.90 ± 0.05 0.87 ± 0.05 0.85 ± 0.06 0.89 ± 0.04 0.84 ± 0.04 0.84 ± 0.03
*p < 0.05 vs. Control at same time point
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or coronary arteries [29], and our measurements in the
aorta are consistent with these prior findings. The MPR
imaging results were supported by ex vivo vascular
reactivity studies, which showed an impaired vasodila-
tory response of the coronary arterioles of HFD mice to
adenosine. Coronary arterioles from HFD mice also had
a reduced response to acetylcholine, showing endothelial
dysfunction as well as impaired passive tone in response
to increasing pressure steps. The finding that impaired
MPR occurs after 18 weeks of HFD is consistent with
the recently-established time course for impaired systolic
strain with dobutamine stress, which occurred at
22 weeks of HFD but not 16 weeks [30]. Furthermore,
we showed that 18 weeks of HFD in mice resulted in in-
creased LV mass and increased LVWT without changes
in LV volumes and peak LV Ecc. Our results in this
mouse model are consistent with prior studies in pa-
tients with obesity and diabetes which have shown that
MPR is progressively reduced in patients with increasing
body weight [3] and in type-2 diabetic patients with in-
creasing haemoglobin A1c [31].
Our vascular reactivity results are consistent with
prior studies by Yamamoto et al. [32] and Calligaris et al.
[7], who have shown impaired endothelium-dependent
relaxation in excised thoracic aortas in response to
acetylcholine in HFD mice at 17 weeks and at 8–16
months post-diet. Furthermore, these results are in line
with prior studies which reported impaired coronary
endothelial function in obese patients [3, 33].
In this study, we showed that HFD mice develop
increased LV mass and LVWT after 18 weeks of feeding.
However, there were no significant differences in LV
systolic function (EF, Ecc, synchrony) between the two
groups of mice. These results agree with a recent study
by Calligaris et al. [7] who showed increased LV mass,
cardiomyocyte hypertrophy and normal systolic function
in HFD mice at 8–16 months of HFD feeding (60 %
calories from fat) using histology, echocardiography and
cardiac catheterization. Our results also agree with a
recent cine DENSE study of HFD mice [30], but disagree
with an older study [26]. In the older study [26], mice
fed a HFD for 5 months showed impaired systolic strain,
torsion and synchrony. However, more recent results
from this group [30] showed that dobutamine-induced
systolic strain impairments occur in mice fed a HFD for
22 weeks, however impaired systolic strain at rest is not
observed until 42 weeks of diet. Another recent study
using high frame-rate cine CMR also showed normal
systolic function in HFD mice (45 % calories from fat) at
20 weeks post-diet and, importantly, demonstrated dia-
stolic dysfunction [8]. Synthesizing results from multiple
studies, the pathophysiology time course appears to
include impaired MPR and increased LV mass and wall
thickness by 18 weeks of HFD, diffuse and perivascular
Fig. 4 a Cumulative arteriolar dose-response curves to adenosine in control and HFD mice at 26 weeks post-diet (*p< 0.05 vs control at same concentra-
tion). b Cumulative dose-response curves to acetylcholine in control and HFD mice at 26 weeks post-diet (*p< 0.05 vs. control at same concentration).
c Passive tone in the control and HFD mice at 26 weeks post-diet (*p < 0.05 vs. control at same pressure)
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fibrosis, dobutamine-inducible impairments in strain,
and possibly subtle diastolic dysfunction around weeks
20–25 of HFD, and impaired resting strain by 42 weeks
of HFD.
Previous studies have used C57Bl/6 mice with different
specific diet compositions to study the effects of obesity,
diabetes and metabolic syndrome on cardiac function [7, 8,
11, 32, 34–37]. Diets vary in terms of percentage of calories
from fat (30–78 %), and in the amounts of carbohydrate,
protein, fatty acids, and sugar [38]. The specific diet
composition can alter the degree of weight gain and the
metabolic pathophysiology. In part due to the variety of
diets, prior studies investigating the effect of HFD on car-
diac function have yielded conflicting results [8, 26, 34].
The mechanisms underlying impaired MPR and cor-
onary vascular reactivity are not completely understood.
Deterioration of the overall endothelium or endothelial
dilatory components is a possibility. Changes in eNOS
have been observed in several HFD models [39–41].
Impaired responses to both adenosine and acetylcholine,
agonists that have well-defined endothelial derived nitric
oxide release for smooth muscle dilation, would indicate
this is likely the case. Furthermore, we also found that
the passive tone in isolated coronary arterioles was
significantly reduced, suggesting a change in the extra-
cellular matrix composition, making the arterioles more
rigid. Correspondingly, using histology, we also showed
significantly higher interstitial fibrosis and a trend
towards increased perivascular fibrosis in the HFD mice.
Similarly, a prior study showed that mice fed a HFD de-
velop increased perivascular fibrosis [32]. This change in
extracellular matrix, especially perivascular fibrosis, may
result in stiffer vessels, thereby affecting the dilatory cap-
acity of these vessels. Regardless of the exact mechanism
underlying the change in vascular reactivity, because the
ability of arterioles to dilate or constrict governs the
degree of blood flow to the capillaries, it is highly likely
that the inability of these coronary arterioles to dilate in
response to adenosine (or acetylcholine and changes in
pressure) is responsible for the significantly reduced
MPR detected by noninvasive imaging.
Several mechanisms have been implicated in the
pathogenesis of obesity- [42] and diabetes [43]-related
cardiac hypertrophy such as insulin resistance, lipotoxi-
city [44, 45], inflammation [46], oxidative stress and
renin-angiotensin-aldosterone system (RAAS) activity.
Fig. 5 a Representative CD31-stained sections of the heart from a control and (b) a HFD mouse. c Capillary density in control and HFD mice. d
Representative Masson’s Trichrome stained sections of the heart from a control and (e) a HFD mouse. f Myocardial interstitial fibrosis in control
and HFD mice (*p < 0.05 vs. control). g Representative Masson’s Trichrome-stained coronary vessels from sections of the heart from a control
mouse and (h) a HFD mouse. i Perivascular fibrosis in control and HFD mice. Scale bars = 50 μm
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Recent studies suggest that low levels of adiponectin in
obesity and diabetes-related disorders may also contrib-
ute to cardiac hypertrophy [47, 48]. Some or all of the
above mentioned mechanisms may be responsible for
the increased LV mass observed in the HFD mice in this
study. With regard to impaired MPR, a prior study
showed that Interleukin-6 (IL-6), a cytokine associated
with obesity, can induce oxidative stress and endothelial
dysfunction by upregulating the angiotensin II type 1
receptor [49]. Additionally, a recent study showed that
Olmesartan, an angiotensin II type 1 receptor blocker,
significantly suppressed HFD-induced vascular endothe-
lial dysfunction and disruption of eNOS in the thoracic
aorta in mice [32]. Thus, upregulation of the angiotensin
II type 1 receptor may be responsible for the reduction
in MPR observed in the HFD mice in this study. Several
factors such as myocardial lipid accumulation and lipo-
toxicity may contribute to the increased cardiac fibrosis
observed in the mice fed a high-fat diet. A recent study
by Abdesselam et al. [50] showed increased myocardial
lipid accumulation along with increased cardiac fibrosis
in mice fed a high-fat and high-sucrose diet. Further-
more, Glenn et al. [44] showed increased cardiac fibrosis
in a mouse model of cardiac steatosis.
Over the time course of the present study, three HFD
mice and one control mouse died. The mice died in
between the imaging sessions, not during CMR or
glucose tolerance testing. One of the high-fat diet mice
that died developed an abdominal tumor and the other
two high-fat diet mice had small abdominal lesions.
Including the present study as well as other studies in
our lab, we have had more than 60 mice in protocols
with 24 weeks of HFD feeding, and these three have
been the only deaths. It is also very rare for mice on the
control diet to die. Other than the mice that died, all the
other mice in the present study were generally healthy
with the exception that the HFD mice were obese.
Conclusion
Using CMR, GTTs, vascular reactivity, and histological
studies, we showed that C57Bl/6 mice fed a HFD for
18–24 weeks are obese and have progressively in-
creased LV mass, progressively decreased MPR, glucose
intolerance, interstitial fibrosis, and reduced coronary
arteriole reactivity with normal capillary density and no
aortic plaque. These studies establish mice fed a HFD
as a model system for the clinical scenario of obese and
diabetic patients with reduced MPR in the absence of
significant coronary artery disease. Future studies using
CMR and gene-modified mice fed a HFD may shed
light on key molecular mechanisms that underlie
myocardial ischemia in obesity and diabetes-related
cardiomyopathy.
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